Please ensure Javascript is enabled for purposes of website accessibility

Pfizer and BioNTech to Potentially Sell 300 Million Doses of Its Coronavirus Vaccine to EU

By Brian Orelli, PhD – Sep 9, 2020 at 2:09PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The duo is in contract negotiations with the European Commission.

Pfizer (PFE -0.63%) and BioNTech (BNTX -1.62%) moved one step closer to potentially selling doses of their coronavirus vaccine, BNT162b2, to EU member states. Investors have known since mid-July that the duo was in talks with the European Commission. But, as governments are apt to do, it's taken awhile to get the deal done.

The sides have completed "exploratory talks" and will now enter "contract negotiations." They are at the point where they've decided how many doses the contract will cover -- 200 million with an option for another 100 million doses -- but haven't determined the cost the EU member states will pay. If they can reach an agreement, Pfizer and BioNTech would begin supplying the vaccine by the end of 2020, subject to an approval by EU regulators.

Doctor giving a shot to a child holding a stuffed animal.

Image source: Getty Images.

The drugmakers announced a deal with the U.S. government in July to sell 100 million doses of BNT162b2 for $19.50 per dose. The government has an option to purchase an additional 500 million doses.

Worldwide, Pfizer and BioNTech expect to have 100 million doses ready by the end of 2020 and approximately 1.3 billion doses available by the end of 2021. The vaccine requires an initial dose and a booster shot, so the actual number of people who can be treated is half of the number of available doses.

BNT162b2 is currently being tested in a phase 2/3 clinical trial, which, as of Monday, had enrolled 25,189 of the expected 30,000 participants. Initial data from the study may be available as early as October, although the exact timing will be based on how quickly people in the clinical trial develop COVID-19, the disease that's caused by the novel coronavirus.

Brian Orelli, PhD and The Motley Fool have no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.